ArticleOncotarget2017

Proteasome inhibitors prevent bi-directional HER2/estrogen-receptor cross-talk leading to cell death in endocrine and lapatinib-resistant HER2+/ER+ breast cancer cells.

Sonja Thaler et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.